Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar 9;2(1):8.
doi: 10.1186/2162-3619-2-8.

Genetic profiles of plasmacytoid (BDCA-4 expressing) DC subtypes-clues to DC subtype function in vivo

Affiliations

Genetic profiles of plasmacytoid (BDCA-4 expressing) DC subtypes-clues to DC subtype function in vivo

Stephen H Wrzesinski et al. Exp Hematol Oncol. .

Abstract

Among the dendritic cell (DC) subsets, plasmacytoid DC's (pDC) are thought to be important in the generation of both antiviral and antitumor responses. While pDC may be useful in developing dendritic cell-based tumor vaccines, the low frequency of these cells in the peripheral blood has hampered attempts to understand their biology. To provide better insight into the biology of pDC, we isolated these unperturbed cells from the peripheral blood of healthy donors in order to further characterize their gene expression. Using gene array technology we compared the genetic profiles of these cells to those of CD14+ monocytes isolated from the same donors and found several immune related genes upregulated in this cell population. This is the first description, to our knowledge, of gene expression in this subset of DCs obtained from the peripheral blood of adult human donors without exposure in vitro to cytokine or growth factors. Understanding the natural genetic profiles of this dendritic cell subtype as well as others such as the BDCA-1 expressing myeloid DCs may enable us to manipulate these cells ex-vivo to generate enhanced DC-based tumor vaccines inducing more robust antitumor responses.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Separation of BDCA-4 subpopulation by MACS and FACS. Representative Flow Cytometry plot evaluating the purity of BDCA-4 populations from Ficol-separated PBMCs obtained from normal healthy donors. Leukocytes stained with BDCA-4-PE and the lymphocyte markers CD3-FITC and CD20-FITC and evaluated by flow cytometry: Prior to sorting (A), after Magnetic Bead Sorting (MACS) (B), and after MACS followed by Fluorescence-Activated Cell Sorting (FACS) (C). R2 indicates the left upper quadrant sorting gate, R3 indicates gate for lymphocytes removed by FACS.
Figure 2
Figure 2
Summary of BDCA-4 dendritic cell genes upregulated (A) and genes involved in the immune response. (A) Biologic processes of genes upregulated at least three fold using the OntoExpress software as discussed in the materials and methods section. (B) List of specific genes upregulated in BDCA-4 cells relative to CD14+ cells. ** Genes confirmed to be upregulated using RT-PCR as discussed in the materials and methods section. Numbers in parentheses indicate two separate values of fold upregulation of the selected upregulated genes confirmed by RT-PCR.

References

    1. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 1996;29:371–380. doi: 10.1002/(SICI)1097-0045(199612)29:6<371::AID-PROS5>3.0.CO;2-B. - DOI - PubMed
    1. Ernstoff MS, Crocenzi TS, Seigne JD. Developing a Rational Tumor Vaccine Therapy for Renal Cell Carcinoma: Immune Yin and Yang. Clin Cancer Res. 2007;13:733s–740s. doi: 10.1158/1078-0432.CCR-06-2064. - DOI - PubMed
    1. Hsu FJ, Benike C, Fagnoni F. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52–58. doi: 10.1038/nm0196-52. - DOI - PubMed
    1. Thurner B, Haendle I, Roder C. Vaccination with Mage-3A1 Peptide-pulsed Mature, Monocyte-derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma. J Exp Med. 1999;190:1669–1678. doi: 10.1084/jem.190.11.1669. - DOI - PMC - PubMed
    1. Kantoff PW, Higano CS, Shore ND. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422. doi: 10.1056/NEJMoa1001294. - DOI - PubMed